Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long Term Follow-up of SAR422459 in Stargardt's Macular Degeneration
NCT01736592Phase 2Active, not recruiting
- Sponsor
- Sanofi
- Start
- Dec 2012
- Primary completion
- Aug 2033
- Modality
- Gene Editing, Gene Silencing, Lentiviral Vectors
- Countries
- 2
01
Overview
A Phase 2 trial of SAR422459 in Stargardt disease (STGD), sponsored by Sanofi. Started Dec 2012; status: active, not recruiting.
02
Drugs
SAR422459
03
Conditions
Stargardt disease (STGD)
Beyond the preview
Go deeper on NCT01736592.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01736592.